https://scholars.lib.ntu.edu.tw/handle/123456789/634562
Title: | Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II) | Authors: | Zeuzem, S Flisiak, R Vierling, J M Mazur, W Mazzella, G Thongsawat, S Abdurakhmanov, D Van Kính, N Calistru, P Heo, J Stanciu, C Gould, M Makara, M SHIH-JER HSU Buggisch, P Samuel, D Mutimer, D Nault, B Merz, M Bao, W Griffel, L H Brass, C Naoumov, N V |
Issue Date: | Oct-2015 | Journal Volume: | 42 | Journal Issue: | 7 | Start page/Pages: | 829 | Source: | Alimentary pharmacology & therapeutics | Abstract: | Alisporivir (ALV) is an oral, host-targeting agent with pangenotypic anti-hepatitis C virus (HCV) activity and a high barrier to resistance. |
URI: | https://www.scopus.com/record/display.uri?eid=2-s2.0-84940788102&doi=10.1111%2fapt.13342&origin=inward&txGid=674e144230fee461c0ee3463fde4fac1 https://scholars.lib.ntu.edu.tw/handle/123456789/634562 |
ISSN: | 02692813 | DOI: | 10.1111/apt.13342 |
Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.